ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Comorbidity"

  • Abstract Number: 2412 • ACR Convergence 2025

    Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis

    Maria Romero Noboa1, Faria Sami2, Almurtada Razok3 and Shahzad Ahmed Sami4, 1University of Alabama at Birmingham, Birmingham, AL, 2The University of Alabama at Birmingham, Birmingham, AL, 3John H Stroger Jr Hospital of Cook County, Chicago, IL, 4DCH Regional Medical Center, Birmingham

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare manifestation of Systemic Lupus Erythematosus (SLE) with increased morbidity and mortality. It has historically been underdiagnosed in…
  • Abstract Number: 1920 • ACR Convergence 2025

    Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis

    Angeles Lopez-Olivio1, Zhigang Duan2, Huifang Lu3, Edwin J. Ostrin2, Robert J. Volk2, Ying Xu2, Sharon H. Giordano4 and Hui Zhao4, 1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 3UT MD Anderson Cancer Center, Houston, TX, 4The University of Texas MD Anderson Cancer Center, Houston

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at elevated risk for lung cancer. Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended for…
  • Abstract Number: 1130 • ACR Convergence 2025

    Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia

    Kiara Tan1, Jiaqi Wang1, Saiajay Chigurupati2, Gregory Challener3, Natalie McCormick1, Sharan Rai4, Florence Porterfield5, Chika Anekwe1, Dong Wook Kim6, Fatima Stanford7, Caroline Apovian8, Hyon K. Choi9 and Chio Yokose10, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, 4Massachusetts General Hospital/Harvard Medical School, Boston, MA, 5Division of Endocrinology, Massachusetts General Hospital, Boston, 6Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, 7Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, 8Brigham and Women's Hospital, Boston, 9MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, 10Massachusetts General Hospital, Waltham, MA

    Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
  • Abstract Number: 0091 • ACR Convergence 2025

    Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Rheumatoid Arthritis: associations with treatment response and comorbidities

    Athena Chin1, susan branford2, Annabelle Small3, malcolm Smith1, monika Kutyna4, Robert King5, Susanna Proudman6, Devendra Hiwase7 and Mihir Wechalekar8, 1Flinders Medical Centre, KURRALTA PARK, South Australia, Australia, 2SA Pathology, Adelaide, 3Flinders University, Bedford Park, South Australia, Australia, 4South Australian Health and Medical Research Institute, Adelaide, 5Flinders Medical Centre, Adelaide, South Australia, Australia, 6Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, 7Royal Adelaide Hospital, Adelaide, 8Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia

    Background/Purpose: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is defined as the detection of recurrent somatic mutations, at a variant allele frequency (VAF) < ![if…
  • Abstract Number: 2383 • ACR Convergence 2025

    The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort

    Benny Rashuamán-Conche1, Rocío Gamboa-Cárdenas2, Victor Pimentel-Quiroz3, Cristina Reategui-Sokolova4, Claudia Elera-Fitzcarrald4, Cesar Pastor-Asurza5, Zoila Rodriguez-Bellido6, Risto Perich-Campos7, Graciela Alarcón8 and Manuel Ugarte-Gil9, 1Hospital Guillermo Almenara Irigoyen, Lima, Lima, Peru, 2Universidad Científica del Sur, Lima, Peru, 3Universidad Científica del Sur, San Isidro, Peru, 4Hospital Guillermo Almenara Irigoyen, Lima, Peru, 5Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, 6Universidad Nacional Mayor de San Marcos, Lima, Peru, 7Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, 8The University of Alabama at Birmingham, Oakland, CA, 9Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru

    Background/Purpose: The CCI has been associated with adverse health-related outcomes in SLE-patients worldwide. Its modified version, the age-adjusted CCI (ACCI) has been associated with organ…
  • Abstract Number: 1894 • ACR Convergence 2025

    Opioid Use Disorder Among Patients with Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis

    Jacob Riegler1, Leah Santacroce2, Karen H. Costenbader3 and Candace Feldman4, 1Cambridge Health Alliance, Harvard Medical School, Somerville, MA, 2Brigham and Women's Hospital, Boston, MA, 3Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital/ Harvard Medical School, Boston

    Background/Purpose: Opioid use disorder (OUD) is associated with high morbidity and mortality and in the U.S. in 2022, resulted in over 81,000 overdose deaths.1 However,…
  • Abstract Number: 1017 • ACR Convergence 2025

    Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network

    James Wei1, Shiow-Ing Wang2 and Ying-Li Lin2, 1Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China), 2Chung Shan Medical University Hospital; China Medical University, Taichung, Taiwan (Republic of China)

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing herpes zoster (HZ). This study aimed to assess the effectiveness of recombinant zoster…
  • Abstract Number: 0077 • ACR Convergence 2025

    Transformer-based multi-omics study identifies important role of glycine, serine and threonine metabolism pathway in rheumatoid arthritis complicated by anemia

    Fanxin zeng1, Jianxin Huang2, Yuanli Wei3, Dongmei Wang3, Jianghua Chen4, Congcong Jian1, Xiaoting Zhu5, Shilin Li5, Jie Zhang5, Tingting Wang3, Caizhen Liu6, Lingli Wei3, Jing Gao3, Jing Zhu7, Qinghua Zou8 and Jianhong Wu3, 1Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital; Medical School, Sichuan University of Arts and Sciences; School of Basic Medical Science, Chengdu University of Traditional Chinese Medicine, Dazhou, China (People's Republic), 2Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China (People's Republic), 3Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, China (People's Republic), 4Dazhou Vocational College of Chinese Medicine, Dazhou, China (People's Republic), 5Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital, Dazhou, China (People's Republic), 6Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, 7Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, Chengdu, China (People's Republic), 8Department of Rheumatology and Immunology, First Affiliated Hospital of Army Medical University, Chongqing, China (People's Republic)

    Background/Purpose: Anemia is a prevalent hematologic complication of rheumatoid arthritis (RA) that exacerbates the disease process and severely impacts clinical performance and treatment strategies. We…
  • Abstract Number: 2330 • ACR Convergence 2025

    Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans – A Retrospective Cohort Study

    Siba Raychaudhuri1, Smriti K Raychaudhuri2, Jessica A. Walsh3, Gail Kerr4, Maureen Dubreuil5, Bernard Ng6, Elizabeth Chang7, Andreas Reimold8 and Liron Caplan9, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2Sacramento VA Medical Center, Davis, CA, 3Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5Boston University School of Medicine, Milton, MA, 6Veteran Affairs, Seattle, WA, 7PVAHCS, Phoenix, AZ, 8Dallas VA Medical Center, Dallas, TX, 9Rocky Mountain Regional VAMC, Aurora, CO

    Background/Purpose: Psoriasis and psoriatic arthritis (PsA) are associated with several comorbid conditions including metabolic disease, chronic kidney disease as well as mental health disorders. However,…
  • Abstract Number: 1883 • ACR Convergence 2025

    Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.

    Batko Bogdan1, Mateusz Szeląg2, Krzysztof Batko3, Magdalena Krajewska-Włodarczyk4, Zbigniew Żuber5, Marcin Stajszczyk6, Brygida Kwiatkowska7 and Tomasz Guzik8, 1Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Kraków, Poland, 2Ministry of Health, Warsaw, Poland, 3Department of Dermatology, University Hospital in Krakow, Poland, Krakow, Poland, 4University of Warmia & Mazury, Olsztyn, Poland, 5Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Krakow, Poland, 6Department of Rheumatology and Autoimmune Diseases, Silesian Center for Rheumatology, Orthopedics and Rehabilitation, Ustroń, Poland, Ustron, Poland, 7Clinic of Early Arthritis, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, Warsaw, Poland, 8BHF Centre for Research Excellence, Centre for Cardiovascular Sciences, The University of Edin-burgh, Edinburgh, UK, Edinburgh, United Kingdom

    Background/Purpose: While the association between psoriatic arthritis (PsA) and cardiometabolic disorders is established, the temporal sequence and progression of these comorbidities remain poorly characterized. To…
  • Abstract Number: 0579 • ACR Convergence 2025

    Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy

    Philip J. Mease1, Nicole Middaugh2, Yolanda Muñoz Maldonado2, Chao Song3, Melissa Eliot2, Robert Low3 and Alexis Ogdie4, 1Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 2CorEvitas, LLC, Waltham, MA, 3UCB, Smyrna, GA, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease affecting the joints, skin, and other regions of the body. It impacts up to 36%…
  • Abstract Number: 2292 • ACR Convergence 2025

    Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study

    Sandra G Pasoto1, Talita Ribeiro2, Nadia Emi Aikawa3, Ana C Medeiros-Ribeiro1, Bruno Borges2, Andre Franco4, Henrique Silva2, Eloisa Bonfa5 and Clovis Artur Silva6, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 2Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, 3Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, 5Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 6University of São Paulo, São Paulo, São Paulo, Brazil

    Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
  • Abstract Number: 1712 • ACR Convergence 2025

    Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center

    Rebecca Haberman1, Nicolas Coudray2, Xu Han2, Morgan Grams2, Eric Oermann2, Aristotelis Tsirigos2 and Jose Scher3, 1NYU Langone Health, New York, NY, 2NYU Grossman School of Medicine, New York, 3New York University School of Medicine, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease that affects both the skin and musculoskeletal system and is frequently associated with a heightened…
  • Abstract Number: 0546 • ACR Convergence 2025

    Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study

    Paras Karmacharya1, Dilli Poudel2, Daniel Shin3, Robert Fitzsimmons3, Leslie Crofford4 and Alexis Ogdie5, 1Vanderbilt University, Nashville, TN, Hermitage, TN, 2Vanderbilt University Medical Center, Nashville, TN, 3University of Pennsylvania, Philadelphia, 4Vanderbilt University Medical Center, Melbourne, AR, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Multimorbidity (≥ 2 chronic conditions) is common in inflammatory diseases such as psoriatic arthritis (PsA), psoriasis (PsO), and axial spondyloarthritis (AxSpA), increasing patient burden…
  • Abstract Number: 2266 • ACR Convergence 2025

    Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study

    Mohammad Movahedi1, Angela Cesta1, Sibel Aydin2, Pooneh Akhavan3, Tetyana Kendzerska4, Claire Bombardier1 and Bindee Kuriya5, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, 3self-employed, Toronto, ON, Canada, 4Ottawa Hospital Research Institute, Mississuaga, ON, Canada, 5University of Toronto - Toronto, Toronto, ON, Canada

    Background/Purpose: Observational studies on RA therapeutic classes have shown conflicting results on their impact on mortality and cancer. When analyzing long-term outcomes, it is essential…
  • 1
  • 2
  • 3
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology